File Description: 

The Duke Antimicrobial Stewardship and Evaluation Team, Duke Pharmacy, and Duke Division of Infectious Diseases have provided updates on COVID-19 therapeutics. DUHS supply of COVID-19 therapeutics is now adequate to consider ambulatory therapies for all tiers of high-risk patient groups with mild/moderate disease. Please refer to this document and Duke CustomID for further information. Updated 03-25-22.

The information on this site is intended solely for the internal use by Duke University Health System, its medical staff, clinicians and staff and any and all content or services available on or through this website is prohibited to be shared with external parties with the exception of those marked as patient communications that would be disclosed to patients.